Refer to the EU Guidelines for pharmacovigilance of pediatric medicines, this paper analyzed the characteristics of adverse reactions in pediatric clinical trials and pediatric populations, and the main points of pharmacovigilance in pediatric populations. The pediatric population is in the stage of growth and development. The frequency and nature of adverse reactions are different from that of adults. According to the physiological and pathological characteristics of the pediatric population, they should be distinguished in terms of adverse reaction reporting and treatment, risk control, signal management, regular safety reports, and post-marketing research. Taking into account the current situation of pharmacovigilance construction during clinical trials in China, accelerate the establishment of a pharmacovigilance system for pediatric clinical trials and strengthen the protection of subjects in pediatric populations.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |